EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advancing Cancer Cachexia Drug Development: Leveraging Biomarkers and Functional Endpoints to Optimize Trial Design

Nada O Othman, Hadir Habib, Doaa M Almeldin, Kyrillus S Shohdy iD

Cancer Reports · 2026-07 · 9 (7)

DOI: 10.1002/cnr2.70613 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Reports, online erschienen am 01.07.2026. Verfasst von Nada O Othman und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Cairo University, Cairo, Egypt. Hauptthemen laut MEDLINE: Cachexia, Neoplasms, Drug Development, Research Design. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cancer‐associated cachexia is a complex, multistage metabolic disorder that markedly contributes to morbidity and mortality in patients with advanced cancer, yet effective pharmacological interventions are lacking. Cachexia drug development has expanded significantly in recent years, with multiple repurposed agents and novel therapies targeting specific pathways entering clinical trials. However, clinical benefit has been limited not only by a lack of promising agents but also, to a large extent, by suboptimal trial design. Recent Findings This article reviews the current evidence to highlight the core principles required to modernize cachexia clinical trials. We emphasize that both repurposed drugs and novel agents have a role, but multimodal approaches integrating pharmacologic intervention with nutritional support and exercise are essential for therapeutic success. Early intervention, guided by predictive biomarkers such as C‐reactive protein and Interleukin‐6, and relatively short study durations focused on rapid clinical benefit are critical considerations.

Conclusion

We demonstrate the importance of moving beyond weight‐based endpoints alone toward functional primary endpoints. Selection of appropriate control arms is crucial and should include multimodal interventions, while trial designs must account for patient heterogeneity and concurrent anticancer therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CachexiaNeoplasmsDrug DevelopmentResearch DesignClinical Trials as TopicHumansAntineoplastic AgentsBiomarkers, TumorBiomarkers

Stichwörter der Autor:innen

cancer cachexiadrug developmenttrial design

Substanzen

Antineoplastic AgentsBiomarkers, TumorBiomarkers

Autor:innen und Institutionen

  • Department of Clinical Oncology, Cairo University, Cairo, Egypt.
  • Department of Oncology, University College London, London, UK.
  • School of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • CRUK Scotland Institute, Glasgow, UK.

ORCID-Profile: Kyrillus S Shohdy

Förderung

  • Cancer Research UK

Zitieren

APA

Othman, N. O., Habib, H., Almeldin, D. M., & Shohdy, K. S. (2026). Advancing Cancer Cachexia Drug Development: Leveraging Biomarkers and Functional Endpoints to Optimize Trial Design. Cancer Reports, 9(7). https://doi.org/10.1002/cnr2.70613

Vancouver

Othman NO, Habib H, Almeldin DM, Shohdy KS. Advancing Cancer Cachexia Drug Development: Leveraging Biomarkers and Functional Endpoints to Optimize Trial Design. Cancer Reports. 2026;9(7). doi:10.1002/cnr2.70613

BibTeX
@article{Othman2026,
  author = {Othman, Nada O and Habib, Hadir and Almeldin, Doaa M and Shohdy, Kyrillus S},
  title = {Advancing Cancer Cachexia Drug Development: Leveraging Biomarkers and Functional Endpoints to Optimize Trial Design},
  journal = {Cancer Reports},
  year = {2026},
  volume = {9},
  number = {7},
  doi = {10.1002/cnr2.70613}
}
Kostenlos starten →